卵巢癌仍然是最杰出的沉默杀手，在所有妇科癌症中发病率和死亡率都很高。晚期患者的诊断由于其无症状进展和不同的组织病理学亚型而导致生存率较低，因此，预后不良和高度复发的恶性肿瘤对化疗具有多药耐药性。表观遗传生物标志物开辟了有趣的研究以对抗OC恶性肿瘤的有希望的途径，此外，它的早期诊断的工具。5-羟甲基胞嘧啶（5-hmC），别名基因组的第六个碱基，是在最近建立的DNA去甲基化过程中形成的中间体，并通过十11易位（TET）家族的酶进行催化。它在调节基因表达中起着重要作用，并引起了对各种癌症类型的兴趣。本文综述了活性DNA去甲基化过程的作用,它的酶和中间5-hmC在卵巢癌的表观遗传景观作为一个有效的生物标志物的临床翻译鉴定的治疗目标，诊断和预后评估。
Ovarian cancer remains the most eminent silent killer, with high morbidity and mortality among all gynaecological cancers. The advanced-stage patient\'s diagnosis has a low survival rate caused by its asymptomatic progression and diverse histopathological sub-types, wherefore in poor prognosis and highly recurring malignancy with multidrug resistance towards chemotherapy. Epigenetic biomarkers open promising avenues of intriguing research to combat OC malignancy, furthermore a tool for its early diagnosis. 5-hydroxymethycytosine (5-hmC), alias the sixth base of the genome, is an intermediate formed during the recently established DNA demethylation process and catalysed via ten-eleven translocation (TET) family of enzymes. It plays a significant role in regulating gene expression and has sparked interest in various cancer types. This
review summarizes the role of active DNA demethylation process, its enzymes and intermediate 5-hmC in epigenetic landscape of ovarian cancer as a potent biomarker for clinical translation in identification of therapeutic targets, diagnostic and prognostic evaluation.
